Reduced doses of emicizumab achieve good efficacy: Results from a national-wide multicentre real-world study in China.

This is the largest study describing patients with HA receiving emicizumab prophylaxis on variant dose regimens in China. We confirmed that nonstandard dose is efficacious and can be considered where full-dose emicizumab is ill affordable.